BioSyent Pharma Establishes Hospital Products Division-Secures First Supply Contract and Orders for New Product
May 13 2008 - 7:58PM
Marketwired
MISSISSAUGA, ONTARIO (TSX VENTURE: RX) announces that it has
established a new Hospital Products Division focused on licensing
or acquiring pharmaceutical products used primiarily in a hospital
setting, and marketing those products across Canada.
The Hospital Products Division of BioSyent Pharma Inc. has
licensed Ciprofloxacin Injection, an anti-bacterial agent, for the
Canadian market. Ciprofloxacin Injection is a generic equivalent to
CIPRO I.V. Minibags 2mg/ml from Bayer Inc. on which the remaining
patents expired recently.
BioSyent Pharma has launched Ciprofloxacin Injection to the
Canadian market and has secured its first supply contract and order
for the product.
BioSyent Inc. continues to concentrate on its pharmaceutical
strategy to source products that have been successfully developed
and proven to be safe and effective; manage these products through
the regulatory process and product registration (approval); and
once approved, market these products in Canada. These
pharmaceuticals will compete in both the branded and generic market
segments and will not require further product development
investment other than regulatory costs.
BioSyent Inc. is a publicly traded specialty pharmaceutical
company whose wholly owned subsidiary, BioSyent Pharma Inc.,
sources, acquires or in-licences pharmaceutical products and
markets these products in Canada. Wholly owned BioSyent subsidiary
Hedley Technologies Ltd. operates the company's legacy business
marketing bio and health friendly non-chemical insecticides.
BioSyent common shares are listed for trading on the TSX Venture
Exchange (TSXV) under the symbol RX.
This press release may contain information or statements that
are forward-looking. The contents herein represent our judgment, as
at the release date, and are subject to risks and uncertainties
that may cause actual results or outcomes to be materially
different from the forward-looking information or statements.
Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future
revenue, operations, profitability and obtaining regulatory
approvals.
The TSX Venture Exchange assumes no responsibility for the
accuracy of this release and neither approves nor disapproves of
the same.
Contacts: BioSyent Inc. Rene C. Goehrum President and CEO (905)
206-0013 (905) 206-1413 (FAX) Email: rgoehrum@biosyent.com Website:
www.biosyent.com
Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Jul 2023 to Jul 2024